Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 221
Filter
1.
Hypertension ; 79(1): 115-125, 2022 01.
Article in English | MEDLINE | ID: mdl-34739768

ABSTRACT

Several GPCRs (G-protein-coupled receptors) have been reported to exhibit tachyphylaxis, which is an acute loss of functional receptor response after repeated stimuli with an agonist. GPCRs are important clinical targets for a wide range of disorders. Therefore, elucidation of the ligand features that contribute to receptor tachyphylaxis and signaling events underlying this phenomenon is important for drug discovery and development. In this study, we examined the role of ligand-binding kinetics in the tachyphylaxis of AT1R (angiotensin II type 1 receptor) using bioluminescence resonance energy transfer assays to monitor signaling events under both kinetic and equilibrium conditions. We investigated AT1R signal transduction and translocation promoted by the endogenous tachyphylactic agonist Ang II (angiotensin II) and its analogs, described previously for inducing reduced receptor tachyphylaxis. Estimation of binding kinetic parameters of the ligands revealed that the residence time of Ang II was higher than that of the analogs, resulting in more sustained Gq protein activation and recruitment of ß-arrestin than that promoted by the analogs. Furthermore, we observed that Ang II led to more sustained internalization of the receptor, thereby retarding its recycling to the plasma membrane and preventing further receptor responses. These results show that the apparent lack of tachyphylaxis in the studied analogs resulted from their short residence time at the AT1R. In addition, our data highlight the relevance of complete characterization of novel GPCR drug candidates, taking into account their receptor binding kinetics as well.


Subject(s)
Angiotensin II/pharmacology , Receptor, Angiotensin, Type 1/metabolism , Signal Transduction/physiology , Tachyphylaxis/physiology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Cell Membrane/drug effects , Cell Membrane/metabolism , HEK293 Cells , Humans , Losartan/pharmacology , Protein Binding , Signal Transduction/drug effects
2.
J Physiol Pharmacol ; 70(5)2019 Oct.
Article in English | MEDLINE | ID: mdl-32009630

ABSTRACT

Age-related macular degeneration (AMD) is a leading cause of central visual loss in people aged over 50 years in well developed countries. Although the anti-vascular endothelial growth factor (VEGF) therapy has become a standard treatment for exudative AMD, its effectiveness may be limited in some cases. We aimed to assess the prevalence of non-responsiveness and tachyphylaxis to anti-VEGF drugs in patients with exudative AMD. The study included 63 initially treatment-naive AMD patients who were analyzed for non-responsiveness and tachyphylaxis to intravitreal injections (IVI) of ranibizumab and aflibercept. The participants were enrolled in a National Healthcare Fund (NHF) Therapeutic Program for the Treatment of Exudative AMD. Best-corrected visual acuity (BCVA) and morphological features of a disease activity assessed in optical coherence tomography (OCT) were evaluated during a 12-month follow-up. The percentage of non-responders achieved 22.2% (14 eyes). No significant correlation was found between the type of VEGF inhibitor and a negative response to therapy. Eight patients (12.7%) developed early tachyphylaxis, which was more common in eyes treated with aflibercept (P = 0.04). The presence of serous pigment epithelium detachment (sPED) at baseline was associated with non-responsiveness as determined by both BCVA (OR 18.2, 95% CI 2.86 - 248; P = 0.021) and OCT features (OR 23.0, 95% CI 1.80 - 321; P = 0.030). Eyes treated with aflibercept showed statistically significant greater BCVA improvement (P = 0.0034) and central retinal thickness (CRT) reduction (P = 0.0129) as compared to ranibizumab group during a loading phase of therapy. In a maintain phase of treatment the differences in BCVA and CRT between these two groups were not statistically significant, however eyes treated with aflibercept still showed better functional and anatomical results. Anti-VEGF therapy is an effective method of treatment for exudative AMD, however some patients may show week or no positive reaction or may develop tachyphylaxis. Awareness of these possible negative effects is an important clinical problem in the long-term management of AMD patients with VEGF inhibitors.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Macular Degeneration/drug therapy , Tachyphylaxis/physiology , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Aged , Aged, 80 and over , Female , Humans , Intravitreal Injections , Macular Degeneration/metabolism , Male , Middle Aged , Ranibizumab/therapeutic use , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Retrospective Studies , Treatment Outcome
3.
ACS Chem Neurosci ; 9(10): 2299-2303, 2018 10 17.
Article in English | MEDLINE | ID: mdl-29671582

ABSTRACT

The threat imposed by the use of psychoactive, illicit drugs on human health and the cost of rehabilitation of the affected individuals is nothing less than billions of dollars per year. Of the psychoactive substance abuse drugs are amphetamine and its analogues like methamphetamine. This Viewpoint intends to draw the attention of readers toward the neurological basis of "falling a prey" to methamphetamine. Attention has been paid toward a rapid desensitizing attribute that develops shortly after the repetitive use of drugs belonging to sympathomimetic agents of this group. Also summarized are the changes in physical characteristics and behavioral changes that could herald the loved ones around the methamphetamine abuser to seek the help of healthcare professionals before permanent and irreversible neurological damage ensues. A brief pharmacology of methamphetamine also precedes the management of these patients, for which no standard procedures exist at present.


Subject(s)
Amphetamine-Related Disorders/therapy , Amphetamines/pharmacology , Amphetamine/pharmacology , Amphetamine-Related Disorders/metabolism , Amphetamine-Related Disorders/physiopathology , Brain/drug effects , Brain/metabolism , Cognition/drug effects , Drug Tolerance/physiology , Humans , Methamphetamine/pharmacology , Mouth/drug effects , Psychoses, Substance-Induced , Skin/drug effects , Synapses/drug effects , Tachyphylaxis/physiology
4.
Chem Biol Drug Des ; 88(5): 677-682, 2016 11.
Article in English | MEDLINE | ID: mdl-27230954

ABSTRACT

Angiotensin II (AngII) is the final active product of the renin enzymatic cascade, which is responsible for sustaining blood pressure. To investigate the effect of N-terminal cyclization on AT1 activation and tachyphylaxis, we designed conformationally constrained analogues with an i-(i + 1) lactam bridge. All analogues presented the same binding coefficient and tachyphylactic index, but some of them such as Cyclo (0-1a) [Glu0 , endo-(Lys1a )]-AngII and Cyclo (0-1a) [Asp0 , endo-(Orn1a )]-AngII showed higher potency. The same tachyphylactic index presented by AngII and cyclic analogues was surprising. We expected a variation after the modification of AngII N-terminal region.


Subject(s)
Angiotensin II/analogs & derivatives , Lactams/chemistry , Receptor, Angiotensin, Type 1/metabolism , Amino Acid Sequence , Angiotensin II/chemical synthesis , Angiotensin II/metabolism , Angiotensin II/pharmacology , Animals , CHO Cells , Circular Dichroism , Cricetinae , Cricetulus , Cyclization , Gastric Fundus/drug effects , Gastric Fundus/physiology , Ligands , Mice , Mice, Inbred C57BL , Peptides/chemical synthesis , Peptides/chemistry , Peptides/pharmacology , Protein Binding , Protein Structure, Secondary , Receptor, Angiotensin, Type 1/chemistry , Receptor, Angiotensin, Type 1/genetics , Tachyphylaxis/physiology
5.
J Adv Nurs ; 70(2): 272-81, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23600762

ABSTRACT

AIM: To report an analysis of the concept of acquired pharmaco-dynamic opioid tolerance. BACKGROUND: Acquired pharmaco-dynamic opioid tolerance is a complex and poorly understood phenomenon associated with strong opioid therapy for managing pain. Critical review of the concept provides greater clarification of the attributes, assisting healthcare professionals in addressing pain and functional management of patients, particularly those with non-malignant pain. DESIGN: Concept analysis. DATA SOURCES: A systematic literature search was undertaken using electronic data bases: CINAHL, British Nursing Index, EMBase, Medline, Pubmed and AMED. All literature reviewed was in English and published between 1976 and 2012. The key search terms were 'chronic non-malignant pain', 'strong opioid therapy' and 'development of acquired pharmaco-dynamic opioid tolerance'; all possible variant terms were also searched. METHOD: The Walker and Avant approach was used to guide the concept analysis. RESULTS: The concept analysis revealed four empirical referents: plasticity, drug administration, reduced analgesic efficacy and increased drug dosing. Tachyphylexia was identified as a borderline case, opioid induced hyperalgesia as a related case and pseudo-tolerance as a contrary case. The antecedent is administration of an opioid analgesic drug and the consequences, increasing opioid drug dose to maintain analgesic effect. CONCLUSION: Untangling the antecedents, empirical referents and consequences of tolerance help healthcare professionals understand its complexities. Improved knowledge may ultimately influence patient outcomes through the construction of better monitoring systems. This concept analysis may also provide insights for policy change and give empirical direction for future research.


Subject(s)
Analgesics, Opioid/pharmacology , Drug Tolerance/physiology , Pain/drug therapy , Abdominal Pain/drug therapy , Abdominal Pain/etiology , Adaptation, Physiological/drug effects , Adult , Analgesics, Opioid/administration & dosage , Back Pain/drug therapy , Back Pain/etiology , Dose-Response Relationship, Drug , Female , Humans , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Male , Middle Aged , Pain/physiopathology , Tachyphylaxis/physiology
6.
Crit Care ; 18(5): 502, 2014 Sep 23.
Article in English | MEDLINE | ID: mdl-25672546

ABSTRACT

Regulatory agencies in North America and Europe recently re-evaluated the safety of metoclopramide. This re-evaluation resulted in recommendations and restrictions in order to minimise the risk of neurological and other adverse reactions associated with the use of metoclopramide. In the ICU, off-label prescription of metoclopramide is common. We have reviewed the evidence for safety, effectiveness and dosing of metoclopramide in critically ill patients. Furthermore, tachyphylaxis is addressed and alternatives are summarised. Finally, recommendations are presented not to abandon use of metoclopramide in ICU patients, because metoclopramide is considered effective in enhancing gastric emptying and facilitating early enteral nutrition.


Subject(s)
Critical Illness/therapy , Drug Prescriptions , Metoclopramide/adverse effects , Metoclopramide/pharmacokinetics , Dose-Response Relationship, Drug , Drug Prescriptions/standards , Humans , Nervous System Diseases/chemically induced , Pharmacokinetics , Tachyphylaxis/physiology
7.
J Neurochem ; 126(6): 739-48, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23795642

ABSTRACT

Nesfatin-1, a peptide whose receptor is yet to be identified, has been involved in the modulation of feeding, stress, and metabolic responses. More recently, increasing evidence supports a modulatory role for nesfatin-1 in autonomic and cardiovascular activity. This study was undertaken to test if the expression of nesfatin-1 in the nucleus ambiguus, a key site for parasympathetic cardiac control, may be correlated with a functional role. As we have previously demonstrated that nesfatin-1 elicits Ca²âº signaling in hypothalamic neurons, we first assessed the effect of this peptide on cytosolic Ca²âº in cardiac pre-ganglionic neurons of nucleus ambiguus. We provide evidence that nesfatin-1 increases cytosolic Ca²âº concentration via a Gi/o-coupled mechanism. The nesfatin-1-induced Ca²âº rise is critically dependent on Ca²âº influx via P/Q-type voltage-activated Ca²âº channels. Repeated administration of nesfatin-1 leads to tachyphylaxis. Furthermore, nesfatin-1 produces a dose-dependent depolarization of cardiac vagal neurons via a Gi/o-coupled mechanism. In vivo studies, using telemetric and tail-cuff monitoring of heart rate and blood pressure, indicate that microinjection of nesfatin-1 into the nucleus ambiguus produces bradycardia not accompanied by a change in blood pressure in conscious rats. Taken together, our results identify for the first time that nesfatin-1 decreases heart rate by activating cardiac vagal neurons of nucleus ambiguus. Our results indicate that nesfatin-1, one of the most potent feeding peptides, increases cytosolic Ca²âº by promoting Ca²âº influx via P/Q channels and depolarizes nucleus ambiguus neurons; both effects are Gi/o-mediated. In vivo studies indicate that microinjection of nesfatin-1 into nucleus ambiguus produces bradycardia in conscious rats. This is the first report that nesfatin-1 increases the parasympathetic cardiac tone.


Subject(s)
Bradycardia/chemically induced , Calcium-Binding Proteins/pharmacology , DNA-Binding Proteins/pharmacology , Heart/drug effects , Heart/innervation , Medulla Oblongata/drug effects , Nerve Tissue Proteins/pharmacology , Neurons/drug effects , Vagus Nerve/drug effects , Animals , Animals, Newborn , Blood Pressure/drug effects , Bradycardia/physiopathology , Calcium/metabolism , Calcium Channels, P-Type/drug effects , Calcium Channels, Q-Type/drug effects , Calcium-Binding Proteins/administration & dosage , Cells, Cultured , DNA-Binding Proteins/administration & dosage , Female , Heart Rate/drug effects , Male , Medulla Oblongata/cytology , Membrane Potentials/drug effects , Microinjections , Nerve Tissue Proteins/administration & dosage , Nucleobindins , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/physiology , Tachyphylaxis/physiology , Telemetry , Vagus Nerve/cytology
8.
Expert Opin Drug Metab Toxicol ; 9(1): 17-29, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23094590

ABSTRACT

INTRODUCTION: Within recent years, glucagon-like peptide 1 receptor agonists (GLP-1-RA) have emerged as a new treatment option for type 2 diabetes. The GLP-1-RA are administered subcutaneously and differ substantially in pharmacokinetic profiles. AREAS COVERED: This review describes the pharmacokinetics and safety aspects of the currently available GLP-1 receptor agonists, liraglutide (based on the structure of native GLP-1), exenatide twice daily and exenatide once weekly (based on exendin-4) in relation to the kinetics and toxicology of native GLP-1. The review is based on electronic literature searches and legal documents in the form of assessment reports from the European Medicines Agency and the United States Food and Drug Administration. EXPERT OPINION: GLP-1-based therapy combines several unique mechanisms of action and have the potential to gain widespread use in the fight against diabetes and obesity. The difference in chemical structure have strong implications for key pharmacokinetic parameters such as absorption and clearance, and eventually the safety and efficacy of the individual GLP-1-RA. The main safety concerns are pancreatitis and neoplasms, for which there are no identifiable differences in risk between the available agents. Antibody formation and injection site reactions are more frequent with the exendin-4-based compounds. The efficacy with regard to Hb(A1c) reduction is superior with the longer-acting agonists, whereas the shorter-acting GLP-1-RA seems to provide greater postprandial glucose control and lower tolerability as a possible consequence of less induction of tachyphylaxis. The future place of these agents will depend on the added safety and efficacy data in the several ongoing cardiovascular outcome trials.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptide 1/agonists , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/pharmacokinetics , Animals , Diabetes Mellitus, Type 2/metabolism , Exenatide , Glucagon-Like Peptide 1/adverse effects , Glucagon-Like Peptide 1/analogs & derivatives , Glucagon-Like Peptide 1/metabolism , Glucagon-Like Peptide 1/pharmacokinetics , Glucagon-Like Peptide 1/therapeutic use , Humans , Hypoglycemic Agents/therapeutic use , Liraglutide , Pancreatitis/chemically induced , Pancreatitis/metabolism , Peptides/adverse effects , Peptides/pharmacokinetics , Peptides/therapeutic use , Tachyphylaxis/physiology , Venoms/adverse effects , Venoms/pharmacokinetics , Venoms/therapeutic use
9.
Am J Physiol Lung Cell Mol Physiol ; 303(11): L953-5, 2012 Dec 01.
Article in English | MEDLINE | ID: mdl-23023969

ABSTRACT

Maintenance of airway tone, prevention of airway obstruction, and acute relief from bronchospasm are key targets of asthma therapy. This role is currently performed by ß-agonists. However, chronic use of ß-agonists to treat asthma is associated with desensitization of ß-agonist signaling and a resultant loss of bronchodilator effect, worsening of airway hyperreactivity, and increased incidence of asthma-related morbidity and mortality. There have been several attempts to identify novel non-ß-agonist bronchodilators including ATP-sensitive potassium channel (K(ATP)) agonists such as cromakalim and its active enantiomer BRL-38227 and the cGMP activators atrial natriuretic peptide (ANP) and BAY 41-22722. However, these either have not made it to clinical trial, required high doses, had little effect in patients, or had a high incidence of side effects. Recent data suggests that a novel bronchodilator target exists, the bitter taste receptor TAS2R. Two recent studies [An SS, Wang WC, Koziol-White CJ, Ahn K, Lee DY, Kurten RC, Panettieri RA Jr, Liggett SB. Am J Physiol Lung Cell Mol Physiol 303: L304-L311, 2012; Pulkkinen V, Manson ML, Säfholm J, Adner M, Dahlén SE. Am J Physiol Lung Cell Mol Physiol. doi:10.1152/ajplung.00205.2012.] provide new understanding of the signaling pathways utilized by TAS2Rs to mediate their bronchodilatory effects and how TAS2R-mediated bronchodilation is affected by ß-agonist signaling desensitization. As our understanding of TAS2Rs and their agonists increases, they move closer to a viable therapeutic option; however, further definition is still required and questions remain to be answered. This editorial focus discusses these studies within the context of existing literature and raises questions and challenges for the future development of bitter (better?) therapies for asthma.


Subject(s)
Bronchodilator Agents/pharmacology , Chloroquine/pharmacology , Muscle Relaxation/physiology , Muscle, Smooth/physiology , Quaternary Ammonium Compounds/pharmacology , Receptors, Adrenergic, beta-2/metabolism , Receptors, G-Protein-Coupled/metabolism , Respiratory Physiological Phenomena , Respiratory System/metabolism , Tachyphylaxis/physiology , Trachea/physiology , Animals , Humans , Male , Receptors, G-Protein-Coupled/agonists
10.
Am J Physiol Lung Cell Mol Physiol ; 303(4): L304-11, 2012 Aug 15.
Article in English | MEDLINE | ID: mdl-22683571

ABSTRACT

Recently, bitter taste receptors (TAS2Rs) were found in the lung and act to relax airway smooth muscle (ASM) via intracellular Ca(2+) concentration signaling generated from restricted phospholipase C activation. As potential therapy, TAS2R agonists could be add-on treatment when patients fail to achieve adequate bronchodilation with chronic ß-agonists. The ß(2)-adrenergic receptor (ß(2)AR) of ASM undergoes extensive functional desensitization. It remains unknown whether this desensitization affects TAS2R function, by cross talk at the receptors or distal common components in the relaxation machinery. We studied intracellular signaling and cell mechanics using isolated human ASM, mouse tracheal responses, and human bronchial responses to characterize TAS2R relaxation in the context of ß(2)AR desensitization. In isolated human ASM, magnetic twisting cytometry revealed >90% loss of isoproterenol-promoted decrease in cell stiffness after 18-h exposure to albuterol. Under these same conditions of ß(2)AR desensitization, the TAS2R agonist chloroquine relaxation response was unaffected. TAS2R-mediated stimulation of intracellular Ca(2+) concentration in human ASM was unaltered by albuterol pretreatment, in contrast to cAMP signaling, which was desensitized by >90%. In mouse trachea, ß(2)AR desensitization by ß-agonist amounted to 92 ± 6.0% (P < 0.001), while, under these same conditions, TAS2R desensitization was not significant (11 ± 3.5%). In human lung slices, chronic ß-agonist exposure culminated in 64 ± 5.7% (P < 0.001) desensitization of ß(2)AR-mediated dilation of carbachol-constricted airways that was reversed by chloroquine. We conclude that there is no evidence for physiologically relevant cross-desensitization of TAS2R-mediated ASM relaxation from chronic ß-agonist treatment. These findings portend a favorable therapeutic profile for TAS2R agonists for the treatment of bronchospasm in asthma or chronic obstructive lung disease.


Subject(s)
Muscle Relaxation/physiology , Muscle, Smooth/physiology , Receptors, Adrenergic, beta-2/metabolism , Receptors, G-Protein-Coupled/metabolism , Respiratory Physiological Phenomena , Respiratory System/metabolism , Tachyphylaxis/physiology , Adrenergic beta-Agonists/pharmacology , Albuterol/pharmacology , Animals , Chloroquine/pharmacology , Humans , In Vitro Techniques , Isoproterenol/pharmacology , Methacholine Chloride/pharmacology , Mice , Muscle Relaxation/drug effects , Muscle, Smooth/drug effects , Receptors, G-Protein-Coupled/agonists , Respiratory Physiological Phenomena/drug effects , Respiratory System/drug effects
11.
J Pharmacol Exp Ther ; 342(2): 399-406, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22570366

ABSTRACT

There is a need to better understand the mechanism of airway hyper-reactivity, a key feature of asthma. Evidence suggests that sphingosine-1-phosphate (S1P) could be a major player in this phenomenon. The purpose of this work was to define the S1P receptor responsible for this phenomenon. We have studied, in the rat, the effect of two S1P synthetic receptor ligands, 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol (FTY720) (which in its phosphorylated form is a potent agonist at each S1P receptor except S1P(2)) and 3-[[2-[4-phenyl-3-(trifluoromethyl)phenyl]-1-benzothiophen-5-yl]methylamino]propanoic acid (AUY954) (a selective S1P(1) agonist) on lung function in vivo. This was complemented by in vitro studies using isolated trachea from the rat, the S1P(3) receptor-deficient mouse, and its wild-type counterpart. After oral administration, FTY720 induced a generalized airway hyper-reactivity to a range of contractile stimuli. This was observed as early as 1 h postdosing, lasted for at least 24 h, and was not subject to desensitization. In both rat and wild-type mouse isolated trachea, preincubation with the active phosphorylated metabolite of FTY720 induced hyper-responsiveness to 5-hydroxytryptamine. This effect was not seen in the isolated tracheas from S1P(3) receptor-deficient mice. AUY954, did not mimic the effect of FTY720 either in vivo or in vitro. Our data are consistent with activation of the S1P pathway inducing a generalized airway hyper-reactivity in rats and mice that is mediated by the S1P(3) receptor. S1P(3) receptor antagonists might prove to be useful as new therapeutic strategies aimed at blocking the airway hyper-reactivity observed in asthma.


Subject(s)
Bronchial Hyperreactivity/metabolism , Lysophospholipids/pharmacology , Receptors, Lysosphingolipid/metabolism , Sphingosine/analogs & derivatives , Albuterol/pharmacology , Animals , Asthma/chemically induced , Asthma/metabolism , Bronchial Hyperreactivity/chemically induced , Bronchoconstriction/drug effects , Fingolimod Hydrochloride , Lung/drug effects , Lung/metabolism , Lysophospholipids/metabolism , Male , Mice , Mice, Inbred C57BL , Propylene Glycols/pharmacology , Rats , Rats, Inbred BN , Receptors, Lysosphingolipid/agonists , Receptors, Lysosphingolipid/antagonists & inhibitors , Sphingosine/metabolism , Sphingosine/pharmacology , Sphingosine-1-Phosphate Receptors , Tachyphylaxis/physiology , Thiophenes/pharmacology , Trachea/drug effects , Trachea/metabolism , beta-Alanine/analogs & derivatives , beta-Alanine/pharmacology
12.
Neurosci Bull ; 28(2): 155-64, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22466126

ABSTRACT

OBJECTIVE: Inflammation at the level of the sensory dorsal root ganglia (DRGs) leads to robust mechanical pain behavior and the local inflammation has direct excitatory effects on sensory neurons including small, primarily nociceptive, neurons. These neurons express the transient receptor potential vanilloid-1 (TRPV1) channel, which integrates multiple signals of pain and inflammation. The aim of this study was to characterize the regulation of the TRPV1 channel by local DRG inflammation and by growth-related oncogene (GRO/KC, systemic name: CXCL1), a cytokine known to be upregulated in inflamed DRGs. METHODS: Activation of the TRPV1 receptor with capsaicin was studied with patch clamp methods in acutely isolated small-diameter rat sensory neurons in primary culture. In vivo, behavioral effects of TRPV1 and GRO/KC were examined by paw injections. RESULTS: Neurons isolated from lumbar DRGs 3 days after local inflammation showed enhanced TRPV1 function: tachyphylaxis (the decline in response to repeated applications of capsaicin) was significantly reduced. A similar effect on tachyphylaxis was observed in neurons pre-treated for 4 h in vitro with GRO/KC. This effect was blocked by H-89, a protein kinase A inhibitor. Consistent with the in vitro results, in vivo behavioral responses to paw injection of capsaicin were enhanced and prolonged by pre-injecting the paw with GRO/KC 4 h before the capsaicin injection. GRO/KC paw injections alone did not elicit pain behaviors. CONCLUSION: Function of the TRPV1 channel is enhanced by DRG inflammation and these effects are preserved in vitro during short-term culture. The effects (decreased tachyphylaxis) are mimicked by incubation with GRO/KC, which has previously been found to be strongly upregulated in this and other pain models.


Subject(s)
Chemokine CXCL1/physiology , Ganglia, Spinal/pathology , Inflammation Mediators/physiology , Sensory Receptor Cells/pathology , TRPV Cation Channels/physiology , Animals , Chronic Pain/etiology , Chronic Pain/metabolism , Chronic Pain/pathology , Female , Ganglia, Spinal/metabolism , Male , Molecular Mimicry/physiology , Primary Cell Culture , Rats , Rats, Sprague-Dawley , Sensory Receptor Cells/physiology , TRPV Cation Channels/agonists , Tachyphylaxis/physiology
13.
Pharmacology ; 89(1-2): 29-36, 2012.
Article in English | MEDLINE | ID: mdl-22302025

ABSTRACT

The in vitro contractile response of the human uterine artery to sumatriptan was compared to that of human cerebral blood vessels. Artery rings were prepared for isometric contraction. Tachyphylaxis to the triptan-induced vascular contraction was observed in the uterine artery, but not in basilar and middle cerebral arteries. To evaluate 5-HT(1) receptor subtypes functionality, concentration-response curves to sumatriptan were performed at 0 and 24 h after uterine artery isolation. Both 10 µmol/l cyanopindolol and 63 nmol/l SB 224,289 (5-HT(1B) receptor antagonists) significantly antagonized the contractile response induced by sumatriptan at 0 h but not after 24 h of uterine artery isolation. The 5-HT(1B/1D) receptor antagonist BRL 15,572 at 10 µmol/l significantly antagonized the sumatriptan contractile response at both experimental conditions. We conclude that the tachyphylaxis to sumatriptan observed in the non-cerebral blood vessels, and not in the cerebral ones, may be due to loss of functionality of the 5-HT(1B) receptor subtype, increasing the safety of triptans.


Subject(s)
Basilar Artery/physiology , Middle Cerebral Artery/physiology , Receptor, Serotonin, 5-HT1B/physiology , Serotonin 5-HT1 Receptor Agonists/pharmacology , Sumatriptan/pharmacology , Tachyphylaxis/physiology , Uterine Artery/physiology , Adult , Basilar Artery/drug effects , Biphenyl Compounds/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Female , Humans , In Vitro Techniques , Male , Middle Aged , Middle Cerebral Artery/drug effects , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/physiology , Pindolol/analogs & derivatives , Pindolol/pharmacology , Piperazines/pharmacology , Piperidones/pharmacology , Serotonin/pharmacology , Serotonin/physiology , Serotonin 5-HT1 Receptor Antagonists/pharmacology , Spiro Compounds/pharmacology , Sumatriptan/antagonists & inhibitors , Time Factors , Uterine Artery/drug effects
14.
J Neurophysiol ; 106(6): 3056-66, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21900509

ABSTRACT

The cold-sensing channel transient receptor potential melastatin 8 (TRPM8) features Ca(2+)-dependent downregulation, a cellular process underlying somatosensory accommodation in cold environments. The Ca(2+)-dependent functional downregulation of TRPM8 is manifested with two distinctive phases, acute desensitization and tachyphylaxis. Here we show in rat dorsal root ganglion neurons that TRPM8 acute desensitization critically depends on phosphatidylinositol 4,5-bisphosphate (PIP(2)) availability rather than PIP(2) hydrolysis and is triggered by calmodulin activation. Tachyphylaxis, on the other hand, is mediated by phospholipase hydrolysis of PIP(2) and protein kinase C/phosphatase 1,2A. We further demonstrate that PIP(2) switches TRPM8 channel gating to a high-open probability state with short closed times. Ca(2+)-calmodulin reverses the effect of PIP(2), switching channel gating to a low-open probability state with long closed times. Thus, through gating modulation, Ca(2+)-calmodulin provides a mechanism to rapidly regulate TRPM8 functions in the somatosensory system.


Subject(s)
Calmodulin/pharmacology , Down-Regulation/drug effects , Neurons/drug effects , Phosphatidylinositol 4,5-Diphosphate/pharmacology , TRPM Cation Channels/metabolism , Tachyphylaxis/physiology , Analysis of Variance , Animals , Biophysics , Calcium/metabolism , Cells, Cultured , Chelating Agents/pharmacology , Cold Temperature , Drug Interactions , Egtazic Acid/analogs & derivatives , Egtazic Acid/pharmacology , Electric Stimulation , Enzyme Inhibitors/pharmacology , Female , Ganglia, Spinal/cytology , Humans , Ion Channel Gating/drug effects , Ion Channel Gating/genetics , Isothiocyanates/pharmacology , Male , Membrane Potentials/drug effects , Membrane Potentials/genetics , Menthol/pharmacology , Patch-Clamp Techniques , Rats , Rats, Sprague-Dawley , TRPM Cation Channels/genetics , Tachyphylaxis/genetics , Time Factors , Transfection
15.
Neurosci Lett ; 503(3): 157-62, 2011 Oct 10.
Article in English | MEDLINE | ID: mdl-21855605

ABSTRACT

The ion channel TRPA1 is activated by a wide variety of noxious stimuli, such as pollutants, products of oxidative tissue damage, and pungent natural products. Many TRPA1 activators are reactive electrophiles that form Michael adducts with cysteine and lysine residues of TRPA1's intracellular N-terminus. Curcumin, the active principle of turmeric root (Curcuma longa), can also form Michael adducts. In order to test the hypothesis that the electrophilic curcumin activates TRPA1, we have performed whole-cell, voltage-clamp analysis on both HEK293 cells expressing human TRPA1 (hTRPA1-HEK) and native mouse vagal neurons. In nominally calcium-free extracellular and intracellular solutions which minimized the chances of calcium-dependent activation of TRPA1, curcumin increased TRPA1 currents in hTRPA1-HEK cells in a concentration-dependent manner (1-30µM) but did not cause block or activation of recombinant TRPM8 and TRPV1. In addition, 7 out of 11 vagal sensory neurons from wild type mice responded to curcumin (30µM) with inward currents (11.6±5.4pA/pF) that were largely reversed by TRPA1 blockers. In marked contrast, neurons from TRPA1-deficient mice did not respond to curcumin (30µM). With physiological levels of calcium added to the external solution to facilitate channel desensitization, curcumin-dependent currents in hTRPA1-HEK cells were completely desensitized and exhibited marked tachyphylaxis upon subsequent application of curcumin. Taken together, these results demonstrate that curcumin causes activation and subsequent desensitization of native and recombinant TRPA1 ion channels of multiple mammalian species.


Subject(s)
Curcumin/pharmacology , Transient Receptor Potential Channels/drug effects , Animals , Calcium/metabolism , Capsaicin/pharmacology , Data Interpretation, Statistical , Extracellular Space/drug effects , Extracellular Space/metabolism , HEK293 Cells , Humans , Mice , Mice, Knockout , Patch-Clamp Techniques , Prostaglandin D2/analogs & derivatives , Prostaglandin D2/pharmacology , Sensory Receptor Cells/drug effects , TRPA1 Cation Channel , TRPM Cation Channels/genetics , Tachyphylaxis/physiology , Transient Receptor Potential Channels/genetics , Vagus Nerve/drug effects
16.
Neuropsychopharmacology ; 36(12): 2498-512, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21796109

ABSTRACT

Rapid tolerance develops to many of nicotine's behavioral and autonomic effects. A better understanding of the spatiotemporal patterns in neuronal activity as a consequence of acute nicotine tolerance (tachyphylaxis) may help explain its commonly found inverted 'U'-shaped biphasic dose-effect relationship on various behaviors. To this end, we employed high-resolution functional magnetic resonance imaging and relative cerebral blood volume (rCBV) as a marker of neuronal activity, to characterize the regional development of acute tolerance as a function of nicotine dose in naïve, anesthetized rats. A single intravenous nicotine injection at 0.1 and 0.3, but not 0.03 mg/kg, significantly increased neuronal activity in many neocortical areas. In contrast, dose-dependent increases in rCBV were most pronounced in limbic regions, such that responses seen at 0.1 mg/kg nicotine in accumbens, hippocampus, amygdala, and several other limbic areas were not seen following 0.3 mg/kg nicotine. Finally, whereas profound tolerance was observed in many cortical regions after the second of two paired nicotine injections at either 0.1 or 0.3 mg/kg, subcortical limbic structures showed only a weak trend for tolerance. Lack of rCBV changes in animals receiving nicotine methiodide, a quaternary nicotine analog that does not cross the blood-brain barrier, supports a direct neuronal effect of nicotine rather than an action on the vasculature. These data provide pharmacodynamic insight into the regional heterogeneity of nicotine tachyphylaxis development, which may be relevant to behavioral and neurobiological mechanisms associated with repeated tobacco consumption.


Subject(s)
Limbic System/drug effects , Limbic System/metabolism , Nicotine/administration & dosage , Tachyphylaxis/physiology , Animals , Dose-Response Relationship, Drug , Male , Rats , Rats, Sprague-Dawley
17.
Am J Physiol Cell Physiol ; 301(3): C587-600, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21653898

ABSTRACT

Transient receptor potential (TRP) ankyrin 1 (TRPA1) is a Ca(2+)-permeant, nonselective cationic channel. It is predominantly expressed in the C afferent sensory nerve fibers of trigeminal and dorsal root ganglion neurons and is highly coexpressed with the nociceptive ion channel transient receptor potential vanilloid 1 (TRPV1). Several physical and chemical stimuli have been shown to activate the channel. In this study, we have used electrophysiological techniques and behavioral models to characterize the properties of TRPA1. Whole cell TRPA1 currents induced by brief application of lower concentrations of N-methyl maleimide (NMM) or allyl isothiocyanate (AITC) can be reversed readily by washout, whereas continuous application of higher concentrations of NMM or AITC completely desensitized the currents. The deactivation and desensitization kinetics differed between NMM and AITC. TRPA1 current amplitude increased with repeated application of lower concentrations of AITC, whereas saturating concentrations of AITC induced tachyphylaxis, which was more pronounced in the presence of extracellular Ca(2+). The outward rectification exhibited by native TRPA1-mediated whole cell and single-channel currents was minimal as compared with other TRP channels. TRPA1 currents were negatively modulated by protons and polyamines, both of which activate the heat-sensitive channel, TRPV1. Interestingly, neither protein kinase C nor protein kinase A activation sensitized AITC-induced currents, but each profoundly sensitized capsaicin-induced currents. Current-clamp experiments revealed that AITC produced a slow and sustained depolarization as compared with capsaicin. TRPA1 is also expressed at the central terminals of nociceptors at the caudal spinal trigeminal nucleus. Activation of TRPA1 in this area increases the frequency and amplitude of miniature excitatory or inhibitory postsynaptic currents. In behavioral studies, intraplantar and intrathecal administration of AITC induced more pronounced and prolonged changes in nociceptive behavior than those induced by capsaicin. In conclusion, the characteristics of TRPA1 we have delineated suggest that it might play a unique role in nociception.


Subject(s)
Ankyrins/physiology , Calcium Channels/physiology , Nociception/physiology , Transient Receptor Potential Channels/physiology , 1-Methyl-3-isobutylxanthine/pharmacology , Action Potentials/drug effects , Action Potentials/physiology , Allyl Compounds/pharmacology , Animals , Ankyrins/agonists , Behavior, Animal/drug effects , Calcium/metabolism , Calcium/pharmacology , Capsaicin/pharmacology , Colforsin/pharmacology , Cyclic AMP-Dependent Protein Kinases/metabolism , Dose-Response Relationship, Drug , Electrophysiological Phenomena/drug effects , Electrophysiological Phenomena/physiology , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Ganglia, Spinal/cytology , Hydrogen-Ion Concentration , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Inhibitory Postsynaptic Potentials/drug effects , Inhibitory Postsynaptic Potentials/physiology , Ion Channel Gating/drug effects , Isocyanates/pharmacology , Maleimides/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice , Mice, Inbred Strains , Mice, Knockout , Miniature Postsynaptic Potentials/drug effects , Miniature Postsynaptic Potentials/physiology , Neurons/drug effects , Neurons/physiology , Nociceptive Pain/chemically induced , Nociceptive Pain/physiopathology , Oocytes/drug effects , Oocytes/metabolism , Phorbol 12,13-Dibutyrate/pharmacology , Protein Kinase C/metabolism , Rats , Rats, Sprague-Dawley , Spermine/pharmacology , Synaptic Transmission/drug effects , TRPA1 Cation Channel , TRPC Cation Channels , TRPV Cation Channels/genetics , Tachyphylaxis/physiology , Transient Receptor Potential Channels/agonists
18.
Bioorg Med Chem Lett ; 20(19): 5658-61, 2010 Oct 01.
Article in English | MEDLINE | ID: mdl-20801039

ABSTRACT

A series of 9-dihydroerythromycin A and B analogues with modification of the desosamine nitrogen have been synthesized and screened for motilin agonist activity, antibiotic activity, tachyphylaxis and hERG channel current inhibition. Small alkyl groups resulted in the potency while compounds with a primary or secondary amine resulted in the low motilin agonist potency. Several compounds were identified as non-antibiotic motilin receptor agonists with minimal tachyphylaxis and low hERG interaction.


Subject(s)
Erythromycin/analogs & derivatives , Receptors, Gastrointestinal Hormone/agonists , Receptors, Neuropeptide/agonists , Amino Sugars/chemistry , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , ERG1 Potassium Channel , Erythromycin/chemical synthesis , Erythromycin/pharmacology , Ether-A-Go-Go Potassium Channels/metabolism , Rabbits , Receptors, Gastrointestinal Hormone/metabolism , Receptors, Neuropeptide/metabolism , Tachyphylaxis/physiology
19.
Brain Res ; 1352: 140-6, 2010 Sep 17.
Article in English | MEDLINE | ID: mdl-20599427

ABSTRACT

Stimulation of nicotinic receptors, specifically the alpha7 subtype, improves sensory inhibition and cognitive function in receptor deficient humans and rodents. However, stimulation with a full agonist, such as nicotine, produces rapid tachyphylaxis of the P20N40-measured sensory inhibition process. 3-(2,4-dimethoxybenzylidine) anabaseine (DMXBA, also GTS-21) selectively activates the alpha7 nicotinic receptor, and in acute administration studies, has been shown to improve deficient sensory inhibition in both humans and rodents with repeated dosing. Unlike nicotine, this partial agonist acted without inducing tachyphylaxis. Here, we assessed the ability of DMXBA to improve sensory inhibition in DBA/2 mice after 7 days of continuous administration via a subcutaneously implanted osmotic minipump. When assessed on day 8, mice receiving saline showed the characteristic deficient sensory inhibition seen with untreated DBA/2 mice. The 25- and 50-mg/ml infusion concentrations of DMXBA, but not the 100-mg/ml, produced significantly improved sensory inhibition in the mice, exclusively through a decrease in test amplitude. No concentration significantly upregulated hippocampal alpha7 receptor levels. DMXBA levels in the brain were higher than plasma at 2 of the 3 concentrations infused. These data suggest that continuous exposure to DMXBA does not significantly affect the underlying responsiveness of the sensory inhibition pathway to this partial agonist, nor cause receptor upregulation, at these relatively low brain concentrations. The ability of DMXBA to maintain its effectiveness during constant administration conditions may be due to an ability to activate alpha7 receptors at low concentrations, and consequently low fractional occupancy of the five possible binding sites on this homomeric receptor.


Subject(s)
Benzylidene Compounds/pharmacology , Cholinergic Agents/pharmacology , Hippocampus/physiology , Pyridines/pharmacology , Receptors, Nicotinic/physiology , Sensation/physiology , Tachyphylaxis/physiology , Animals , Benzylidene Compounds/administration & dosage , Benzylidene Compounds/blood , Benzylidene Compounds/metabolism , Brain/drug effects , Brain/metabolism , Hippocampus/drug effects , Mice , Mice, Inbred DBA , Pyridines/administration & dosage , Pyridines/blood , Pyridines/metabolism , Receptors, Nicotinic/drug effects , Receptors, Nicotinic/genetics , Sensation/drug effects , Up-Regulation , alpha7 Nicotinic Acetylcholine Receptor
20.
Can J Physiol Pharmacol ; 88(6): 668-75, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20628433

ABSTRACT

A profound tachyphylaxis of the acute nocifensive flinching (pain) response to subcutaneous injection of endothelin-1 (ET-1) into the hind paw footpad is shown by the reduced response to a second injection. Flinching from the second injection was 20% +/- 5%, 57% +/- 18%, 79% +/- 35%, and 100% +/- 17% of that from the first injection (both 200 micromol/L, 2 nmol) at respective intervals of 24, 30, 48, and 72 h. Inhibition of afferent impulses by local anesthesia of the sciatic nerve, reducing initial flinching to 6%-13% of control, did not affect the tachyphylaxis for the second injection at 24 h. There was no cross-desensitization between formalin and ET-1 injected sequentially into the same paw. Suppression of descending inhibitory effects from endogenous opiates by naloxone (5-8 mg/kg, i.p.), given 30 min before the second ET-1 injection, did not prevent tachyphylaxis. Diffuse effects caused by an initial subcutaneous ET-1 injection into the tail or forepaw resulted in sensitization of the response to ET-1 in the hind paw, rather than tachyphylaxis. In contrast, selective inhibition of local ETA receptors during the initial administration of ET-1, by the antagonist BQ-123 (3.2 mmol/L), reduced tachyphylaxis of nocifensive flinching. Therefore, prolonged pain tachyphylaxis is not due to reduced responsiveness of the CNS, but rather depends on the functional sensitivity or availability of peripheral ET(A) receptors.


Subject(s)
Central Nervous System/physiology , Endothelin-1/pharmacology , Pain/chemically induced , Tachyphylaxis/physiology , Anesthetics/pharmacology , Animals , Endothelin A Receptor Antagonists , Endothelin-1/administration & dosage , Foot/innervation , Formaldehyde/administration & dosage , Formaldehyde/pharmacology , Hindlimb/drug effects , Hindlimb/innervation , Hyperalgesia/chemically induced , Male , Naloxone/pharmacology , Pain Measurement , Peptides, Cyclic/pharmacology , Rats , Rats, Sprague-Dawley , Sciatic Nerve/drug effects , Time Factors , Touch
SELECTION OF CITATIONS
SEARCH DETAIL
...